Announced details
Formulation development related to transdermal delivery, and the development, manufacture and sale of pharmaceuticals
Daito Pharmaceutical Co.,Ltd. has a track record of doing business with more than 90% of pharmaceutical companies in Japan.
The companies entered into an agreement covering the development of transdermal pharmaceutical formulations. They will begin discussions and activities aimed at building future business and operational partnerships.
Based in Chuo-ku, Tokyo, with Ariyoshi Yasushi (有吉 泰) as President. It is a core operating company of the artience Group. The company operates polymer and coating-related businesses and, in prescription pharmaceuticals, provides formulation, polymer synthesis and production technologies for transdermal formulations through its CDMO business.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Transdermal formulations (TDDS formulations) |
| Counterparty | トーヨーケム株式会社 |
| Counterparty overview | Based in Chuo-ku, Tokyo, with Ariyoshi Yasushi (有吉 泰) as President. It is a core operating company of the artience Group. The company operates polymer and coating-related businesses and, in prescription pharmaceuticals, provides formulation, polymer synthesis and production technologies for transdermal formulations through its CDMO business. |
| Relationship with the Company | The companies entered into an agreement covering the development of transdermal pharmaceutical formulations. They will begin discussions and activities aimed at building future business and operational partnerships. |
| Contract Date | 7 April 2026 |
| Applicable area | Formulation development related to transdermal delivery, and the development, manufacture and sale of pharmaceuticals |
| Usage history | Daito Pharmaceutical Co.,Ltd. has a track record of doing business with more than 90% of pharmaceutical companies in Japan. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To mutually leverage the expertise and capabilities each company has in the development and production of transdermal formulations, clinical trials, regulatory affairs, quality assurance and active pharmaceutical ingredient manufacturing.